SpringWorks Therapeutics Inc (NAS:SWTX)
$ 36.12 -0.08 (-0.22%) Market Cap: 2.68 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 4.71 GF Score: 40/100

SpringWorks Therapeutics Inc To Discuss The DeFi Trial Data Call Transcript

May 24, 2022 / 12:30PM GMT
Release Date Price: $33.68 (-11.37%)
Operator

Good morning and welcome to the SpringWorks Therapeutics conference call to discuss the Phase 3 DeFi topline -- sorry, Phase 3 DeFi trial topline results. At this time, I would like to turn the call over to Kim Diamond, Vice President of Communications and Investor Relations.

Kim Diamond
SpringWorks Therapeutics, Inc. - VP, Communications & IR

Thank you, Kevin, and welcome to the SpringWorks Therapeutics conference call to discuss the topline data from our Phase 3 DeFi trial evaluating nirogacestat in adult patients with progressing desmoid tumors. Leading the call today will be SpringWorks' CEO, Saqib Islam. Saqib is joined by our Chief Development Officer, Dr. Mary Smith; and our Chief Operating Officer, Dr. Badreddin Edris.

Following our prepared remarks, we will be taking questions. Slides to accompany this conference call are posted in the Investors and Media section of our website at www.springworkstx.com and an audio webcast with the corresponding slides is also available

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot